- Home
- HLVX vs ANL Comparison
HLVX vs ANL Comparison
Compare HLVX & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- ANL
- Stock Information
- Founded
- HLVX 2020
- ANL 2004
- Country
- HLVX United States
- ANL Cayman Islands
- Employees
- HLVX N/A
- ANL N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- ANL
- Sector
- HLVX Health Care
- ANL
- Exchange
- HLVX Nasdaq
- ANL Nasdaq
- Market Cap
- HLVX 83.7M
- ANL 73.8M
- IPO Year
- HLVX 2022
- ANL 2023
- Fundamental
- Price
- HLVX $1.87
- ANL $1.82
- Analyst Decision
- HLVX Hold
- ANL Strong Buy
- Analyst Count
- HLVX 5
- ANL 2
- Target Price
- HLVX $2.33
- ANL $9.00
- AVG Volume (30 Days)
- HLVX 219.8K
- ANL 10.1K
- Earning Date
- HLVX 05-08-2025
- ANL 06-10-2025
- Dividend Yield
- HLVX N/A
- ANL N/A
- EPS Growth
- HLVX N/A
- ANL N/A
- EPS
- HLVX N/A
- ANL N/A
- Revenue
- HLVX N/A
- ANL N/A
- Revenue This Year
- HLVX N/A
- ANL N/A
- Revenue Next Year
- HLVX N/A
- ANL N/A
- P/E Ratio
- HLVX N/A
- ANL N/A
- Revenue Growth
- HLVX N/A
- ANL N/A
- 52 Week Low
- HLVX $1.34
- ANL $1.10
- 52 Week High
- HLVX $15.60
- ANL $8.88
- Technical
- Relative Strength Index (RSI)
- HLVX 51.02
- ANL 45.00
- Support Level
- HLVX $1.82
- ANL $1.71
- Resistance Level
- HLVX $1.89
- ANL $2.10
- Average True Range (ATR)
- HLVX 0.07
- ANL 0.09
- MACD
- HLVX -0.02
- ANL 0.01
- Stochastic Oscillator
- HLVX 22.73
- ANL 28.21
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.